Nangibotide TFA

• CAT Number: I043952
• Molecular Formula: C56H83F3N14O24S2
• Molecular Weight: 1457.46
• Purity: ≥95%
• IUPAC Name: (4S)-4-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2R)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;2,2,2-trifluoroacetic acid
• InChI: InChI=1S/C54H82N14O22S2.C2HF3O2/c1-25(2)19-29(55)47(83)64-32(9-13-38(56)70)50(86)65-33(11-15-42(75)76)51(87)66-34(12-16-43(77)78)52(88)68-36(21-44(79)80)53(89)60-26(3)46(82)58-22-39(71)61-31(10-14-41(73)74)49(85)67-35(20-27-5-7-28(69)8-6-27)48(84)59-23-40(72)62-37(24-91)54(90)63-30(45(57)81)17-18-92-4;3-2(4,5)1(6)7/h5-8,25-26,29-37,69,91H,9-24,55H2,1-4H3,(H2,56,70)(H2,57,81)(H,58,82)(H,59,84)(H,60,89)(H,61,71)(H,62,72)(H,63,90)(H,64,83)(H,65,86)(H,66,87)(H,67,85)(H,68,88)(H,73,74)(H,75,76)(H,77,78)(H,79,80);(H,6,7)/t26-,29-,30-,31-,32-,33-,34-,35-,36-,37-;/m0./s1
• InChIKey: NBDAFBVZUMXHCK-YEZKNTNWSA-N
• SMILES: C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)N.C(=O)(C(F)(F)F)O

Nangibotide TFA（Cat No.:I043952）is a synthetic peptide and Toll-like receptor 2 (TLR2) antagonist, developed to modulate the innate immune response in inflammatory and septic conditions. By selectively inhibiting TLR2 signaling, Nangibotide TFA reduces the release of pro-inflammatory cytokines, helping to restore immune balance and prevent immune overactivation. It is under investigation for therapeutic use in sepsis and systemic inflammatory response syndrome (SIRS). The trifluoroacetate (TFA) salt form enhances peptide stability and handling. Nangibotide TFA is a promising candidate in immunology research and critical care drug development.